Tag:
Alnylam Pharmaceuticals
Latest Headlines
Latest Headlines
Alnylam scores efficacy data with PCSK9 drug
The data show that the small company has a horse in the race to advance PCSK9-targeting drugs as a brand new category of treatments for lowering LDL cholesterol.
Tekmira seeks court's rejection of Alnylam drug delivery patent suit
Tekmira Pharmaceuticals ($TKMR) fired back at Alnylam Pharmaceuticals ($ALNY) in federal court this week, with an attempt to get rid of the Massachusetts company's patent lawsuit over siRNA and lipid nanoparticle drug delivery technology.
Alnylam identifies who's getting ax
Alnylam Pharmaceuticals ( $ALNY ) has detailed plans for laying off 52 workers, part of a broad effort to slash its RNA workforce 33%. The Boston Business Journal reports that the biotech told state
Ensysce says carbon nanotubes delivered cancer drug
Ensysce Biosciences says early in vivo experiments using single-walled carbon nanotubes to deliver siRNA drugs to cancer tumors have been so promising, the company will proceed to human clinical
Alnylam cutting third of jobs to devote cash to lead RNAi programs
Alnylam Pharmaceuticals ( $ALNY ), a developer of RNA-interference (RNAi) drugs, is axing about 33% of its workforce in a restructuring plan that aims to steer the company's dollars into developmental
UPDATED: Alnylam throws legal punch in patent fight with RNAi tech partner Tekmira
This is growing nastier. Alnylam Pharmaceuticals ( $ALNY ) has fired the latest round—this time in federal court—in an ongoing patent feud with development partner Tekmira Pharmaceuticals (...
Biotech execs leave J.P. Morgan with mixed feelings about year ahead
By John Carroll, Mark Hollmer and Ryan McBride
Wheeling and dealing at J.P. Morgan 2012 Launch slideshow >>
Every year everyone who either qualifies as a top dealmaker in biotech or
Alnylam, Arrowhead join forces on RNAi tech
Alnylam Pharmaceuticals has sealed a new collaboration and licensing deal with Arrowhead Research Corp., giving it access to crucial drug delivery technology once owned by Swiss drug giant Roche.
Countering skeptics, Alnylam claims pioneering first in RNAi cholesterol study
Facing off against some deep-seated skepticism about the future of RNAi drug development, Alnylam ( $ALNY ) has pushed out a preliminary assessment of a small Phase I study demonstrating some dramatic
Alnylam, Medtronic RNAi drug-device combo wows with preclinical data
For years now, scientists have touted the enormous promise of using RNAi treatments to turn off bad genes that cause disease, but delivering the drugs effectively to their target cells, particularly
